

Amendments to the Claims

Kindly amend claims 12, 13, 14, 29, 31, 33 and 34.

Kindly cancel claims ~~28~~ and ~~30~~.

Kindly add new claims 35-37.

1-11 (Previously cancelled)

12. (Currently amended) A composition for treating ~~or preventing~~ herpes group viral infections, said composition comprising activated autologous lymphocytes effective against said viral infections, said activated autologous lymphocytes being obtained by culturing autologous lymphocytes derived from a herpes group virally infected patient, or an immunodeficient or immunosuppressed patient due to herpes group viral infection, in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, said virally infected patient or ~~an~~ said immunodeficient or immunosuppressed patient to be provided with said composition.

D1
13. (Currently amended) A method for preparing a composition for treating ~~or preventing~~ herpes group viral infections, said method comprising deriving autologous lymphocytes from a herpes group virally infected patient or an immunodeficient or immunosuppressed patient due to herpes group viral infection, to be provided with said composition, and culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes.

14. (Currently amended) A method for ~~preventing or~~ treating herpes group viral infections ~~of herpes groups~~, said method comprising deriving autologous lymphocytes from a herpes

group virally infected patient, or an immunodeficient or immunosuppressed patient due to herpes group viral infection, culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, and administering said activated autologous lymphocytes to said patient from which said autologous lymphocytes were derived.

15. (Previously presented) The composition according to claim 12, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

16. (Previously presented) The composition according to claim 15, wherein a protein is added to said cell-suspended solution.

17. (Previously presented) The composition according to claim 16, wherein said protein is human albumin.

18. (Previously presented) The composition according to claim 12, wherein said culture medium further comprises cytokines.

19. (Previously presented) The method according to claim 13, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

20. (Previously presented) The method according to claim 19, wherein a protein is added to said cell-suspended solution.

21. (Previously presented) The method according to claim 20, wherein said protein is human albumin.

22. (Previously presented) The method according to claim 13, wherein said culture medium further comprises cytokines.

23. (Previously presented) The method according to claim 14, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

24. (Previously presented) The method according to claim 23, wherein a protein is added to said cell-suspended solution.

25. (Previously presented) The method according to claim 24, wherein said protein is human albumin.

26. (Previously presented) The method according to claim 23, wherein said activated autologous lymphocytes having a cell concentration in the range of 1×10^4 parts/lit. to 1×10^8 parts/lit. are administered to same patient at a time.

27. (Previously presented) The method according to claim 23, wherein said culture medium further comprises cytokines.

28. (Cancelled)

29. (Currently amended) The composition according to claim ~~28~~ 12, wherein said herpes group viral infection ~~of herpes groups~~ is an Epstein-Barr virus infection.

30. (Cancelled)

13/ 31. (Currently amended) The method according to claim 30 13, wherein said herpes
group viral infection ~~of herpes groups~~ is an Epstein-Barr virus infection.

32. (Previously presented) The method according to claim 14, wherein said patient
is virally infected, immunodeficient or immunosuppressed due to an Epstein-Barr virus infection.

33. (Currently amended) The composition according to claim ~~28~~ 29, wherein said herpes
group viral infection ~~of herpes groups~~ is a herpes simplex virus infection.

34. (Currently amended) The method according to claim 30 13, wherein said herpes
group viral infection ~~of herpes groups~~ is a herpes simplex virus infection.

35. (New) The composition according to claim 12, wherein the activated autologous
lymphocytes are T-lymphocytes.

36. (New) The method according to claim 13, wherein the activated autologous
lymphocytes are T-lymphocytes.

37. (New) The method according to claim 14, wherein the activated autologous
lymphocytes are t-lymphocytes.
